The efficacy and safety of eltrombopag in treating TKI-induced thrombocytopenia in patients with chronic myeloid leukemia
Li Liu,
Yilin Chen,
Yan Liang,
Li Meng,
Jingming Guo,
Chuancai Liu,
Zhe Zhao,
Jing Zou,
Wenjuan He,
Jiangzhao Zhang,
Zhenya Hong,
Caixia Liang,
Xianjie Fu,
Hui Wu,
Youshan Zhang,
Yanli Zhang,
Weiming Li
Affiliations
Li Liu
Department of hematology, Minda Hospital of Hubei Minzu University, Enshi, People’s Republic of China
Yilin Chen
Department of hematology, Union Hospital, Tongji Medical College of Huazhong, University of Science and Technology, Wuhan, People’s Republic of China
Yan Liang
Department of Hematology, Jingzhou Central Hospital, Yangtze University, Jingzhou, People’s Republic of China
Li Meng
Department of hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
Jingming Guo
Department of hematology, Yi Chang Central People’s Hospital, The First College of Clinical Medical Science, China Three Gorges University, Yichang, People’s Republic of China
Chuancai Liu
Department of hematology, Central Hospital of Ezhou City, Ezhou, People’s Republic of China
Zhe Zhao
Department of hematology, Minda Hospital of Hubei Minzu University, Enshi, People’s Republic of China
Jing Zou
Department of hematology, Union Hospital, Tongji Medical College of Huazhong, University of Science and Technology, Wuhan, People’s Republic of China
Wenjuan He
Department of hematology, Union Hospital, Tongji Medical College of Huazhong, University of Science and Technology, Wuhan, People’s Republic of China
Jiangzhao Zhang
Department of Hematology, Jingzhou Central Hospital, Yangtze University, Jingzhou, People’s Republic of China
Zhenya Hong
Department of hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
Caixia Liang
Department of hematology, Jingzhou First People’s Hospital, The First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China
Xianjie Fu
Department of hematology, Central Hospital of Ezhou City, Ezhou, People’s Republic of China
Hui Wu
Department of hematology, Hanchuan people's Hospital, Hanchuan, People’s Republic of China
Youshan Zhang
Department of hematology, Jingzhou First People’s Hospital, The First Affiliated Hospital of Yangtze University, Jingzhou, People’s Republic of China
Yanli Zhang
Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China
Weiming Li
Department of hematology, Minda Hospital of Hubei Minzu University, Enshi, People’s Republic of China
ABSTRACTThrombocytopenia is one of the most common hematological adverse reactions in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKI) therapy, causing life-threatening bleeding cases. However, there are fewer therapeutic drugs for TKI-induced thrombocytopenia. Eltrombopag is a non-peptide thrombopoietin receptor agonist used for the treatment of immune thrombocytopenia， aplastic anemia, and hepatitis C-associated thrombocytopenia. Nevertheless, studies of eltrombopag for TKI-induced thrombocytopenia are still lacking. This study retrospectively analyzed the clinical and test data of 21 CML patients with TKI-related thrombocytopenia. The results demonstrated that the median baseline value of thrombocytopenia in the 21 CML patients was 15.57 × 109/L [2–28 × 109/L]. Following treatment with eltrombopag, 16 patients had a significant increase in their platelet levels. The peak median for platelet increase in effective responders was 145.12 × 109/L (51–460 × 109/L). However, 5 patients failed to respond to eltrombopag. Moreover, 4 of the 21 patients enrolled had adverse reactions, including reversible liver function impairment, palpitation, headache, insomnia, and loss of appetite. Nonetheless, no cases of disease progression, thrombotic events, or myelofibrosis were observed. Hence, eltrombopag may be a useful adjunctive therapy for relieving TKI-related thrombocytopenia in patients with CML.
